We are thrilled that the FDA has cleared our IND application for our first-in-class oral STAT6 degrader, KT-621. As the first #TPD company to advance a degrader for #immunology into clinical trials, this exciting milestone highlights our commitment to delivering potentially differentiated solutions for patients suffering from immuno-inflammatory diseases, and we could not have accomplished this without the hard work of our amazing team. Read the full press release: https://bit.ly/47Y32wo #RevolutionizingImmunology
Kymera Therapeutics
Biotechnology Research
Watertown, MA 30,372 followers
Inventing a new class of medicines using Targeted Protein Degradation
About us
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.
- Website
-
http://www.kymeratx.com
External link for Kymera Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Watertown, MA
- Type
- Public Company
- Founded
- 2016
Locations
-
Primary
500 North Beacon Street
4th Floor
Watertown, MA 02472, US
Employees at Kymera Therapeutics
Updates
-
Congratulations to our CMO, Jared Gollob, for being recognized as part of the PharmaVoice 100 most innovative and impactful individuals in the #lifescience industry! We’re inspired by Jared’s leadership and vision as we continue to advance a new class of transformative medicines for patients. Learn more: https://bit.ly/3BCeJwJ #PharmaVoice100 #Leadership #Biotech #ReinventingMedicine
-
We’re working to revolutionize the treatment of immuno-inflammatory diseases by building an industry-leading #immunology pipeline of oral degrader medicines. Check out our presentation at the European Academy of Dermatology and Venereology 2024 Congress highlighting new preclinical data on KT-621, our first-in-class, oral #STAT6 degrader: https://bit.ly/4dmbfLY #EADVCongress #RevolutionizingImmunology
-
Today, our team will participate in a fireside chat at the Cantor Fitzgerald Global #Healthcare Conference where they’ll discuss the latest developments across our exciting pipeline of degrader medicines. Listen to the live webcast here: https://bit.ly/3MsclLb #CantorHCC
-
Today, Dapeng Chen will present at the International Society for the Study of Xenobiotics and JSSX meeting showcasing how we’re pushing the field forward with our predictive modeling capabilities that reflect our deep knowledge and understanding of the interplay between targets and drug properties. #ISSX2024 #ReinventingMedicine #Pioneer
-
Today we recognize #AtopicEczemaDay and hope to increase awareness and understanding for this chronic, inflammatory condition and the challenges faced by patients living with this disease. And at Kymera, we’re driven to revolutionize the treatment of immuno-inflammatory diseases by building an industry leading pipeline of oral medicines. #RevolutionizingImmunology #AtopicEczemaUnfiltered
-
This week, our team celebrated #HispanicHeritageMonth with a fun social hour and learned about the history of Hispanic dance styles - including an amazing demo and lesson with Kymerian Alexia Pico, PMP from our Quality team! #Belong
-
Great article in Healio today featuring our CMO, Jared Gollob! He discusses our recent #publication in the Journal of Investigative Dermatology highlighting the central role of #IRAK4 signaling in inflammation in HS patients and the transformative potential of KT-474, our first-in-class IRAK4 degrader: https://bit.ly/47n3mVa #RevolutionizingImmunology
-
Don’t miss our CMO Jared Gollob's presentation at the H.C. Wainwright & Co., LLC Global Investment Conference this morning, where he’ll discuss how we’re leveraging our deep scientific expertise to develop next-generation oral small molecule degrader medicines in #immunology. Live webcast here: https://bit.ly/3XrQIkd #RevolutionizingImmunology
-
Today we’ll discuss our innovation in the #TPD space, including what’s ahead for Kymera, at the Morgan Stanley Annual Global #Healthcare Conference. Listen to the live webcast of our fireside chat here: https://bit.ly/4g78MHP